Researchers are studying whether these widely used weight-loss drugs may also be future treatments for alcohol abuse.

One in eight Americans is currently taking a GLP-1 to lose weight or treat a chronic condition.

Novo Nordisk (NVO) plans to run studies on how its GLP-1 class of weight loss/diabetes drug can help people deal with addiction, Martin Holst Lange, the Danish pharma’s head of development, told an ...

Ash will provide at-home biomarker testing to Noom users to provide insights into key health markers linked to chronic ...

Ash provides the at-home testing operational backbone for Noom’s new Proactive Health Microdose GLP-1Rx Program ...

The MarketWatch News Department was not involved in the creation of this content. Studies presented at Obesity Week 2025 validate the test's ability to predict weight-loss response to GLP-1 drugs like ...

Lexaria Bioscience (LEXX) provides the following final primary and major secondary efficacy endpoint results update on its Phase 1b, 12-week ...

GLP-1 weight loss drugs are proving beneficial for people struggling with obesity and diabetes, but there is another surprising side effect coming to light.

There is no exact known number of GLP-1 patients who say their say their sense of taste has changed since starting the ...

PHOENIX (AZFamily) — If you’re worried about your pet putting on some extra pounds, especially during the holiday season, there may be a solution soon. Researchers just launched a clinical study ...

Studies presented at Obesity Week 2025 validate the test's ability to predict weight-loss response to GLP-1 drugs like semaglutide, including in diverse patient populations and post-bariatric surgery ...